Dingxin Recipe III resolves atherosclerotic inflammation via revitalizing Regulatory T cell lineage fidelity associated with fatty acid oxidation metabolic reprogramming - PubMed
3 hours ago
- #Atherosclerosis
- #Metabolic reprogramming
- #Regulatory T cells
- Dingxin Recipe III (DXR III) addresses atherosclerotic inflammation by revitalizing Regulatory T cell (Treg) lineage fidelity through fatty acid oxidation (FAO) metabolic reprogramming.
- Atherosclerosis is characterized by unresolved inflammation due to Treg dysfunction, with FAO being a critical metabolic checkpoint often compromised under metabolic stress.
- Current lipid-lowering therapies like statins may not correct Treg metabolic defects and can introduce additional metabolic issues.
- The study used an integrated systems pharmacology approach, including serum pharmacochemistry, multi-omics profiling, and flow cytometry, to explore DXR III's mechanism in ApoE-/- mice on a high-fat diet.
- DXR III treatment attenuated atherosclerotic progression, identified 254 bioactive constituents, and restored FAO flux, improving Treg differentiation and stability.
- DXR III promoted Treg redistribution to plaque sites and inhibited their trans-differentiation into Th1-like or Th17-like phenotypes, unlike Simvastatin, which led to Th17 accumulation.
- DXR III maintained Th17 homeostasis, eliminated pathogenic non-classical Th17 subsets, and regulated both lipid and glucose metabolism.
- The findings suggest DXR III as a promising candidate for comprehensive cardiovascular protection by modulating FAO to correct immune imbalance in atherosclerosis.